|
Réf :
 Collard
HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ et al. Acute
exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care
Med 2007;176:636-43
Costabel U, King TE. International consensus statement on idiopathic
pulmonary fibrosis. Eur Respir J 2001;17:163-7
Demedts
M, Behr J, Buh R, Costabel U, Dekhuijzen R, Jansen HM et
al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Eng
J Med 2005;353:2229-42
Gribbin
G, Hubbard RB, Le jeune I, Smith CJP, West J, Tata LJ. Incidence and
mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006;61:980-5
Gross
TJ, Hunninghake GW. Idiopathic
pulmonary fibrosis. N Eng J Med 2001;345:517-25
Hunninghake
GM. Antioxidant therapy for idiopathic pulmonary fibrosis.
N Engl J Med
2005 Nov 24;353(21):2285-7
Kim DS, Collard HR, King TE. Classification and natural history of the
idiopathic interstitial pneumonias. Proc Am Thorac Soc
2006;3:285-92
Raghu
G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE for
the idiopathic pulmonary fibrosis study group. A
placebo-controlled trial of interferon gamma-1b in patients with
idiopathic pulmonary fibrosis. N Eng J Med 2004;350:125-33
Ziesche R et al. A preliminary study of long term treatment with
interferon gamma-1b and low-dose prednisolone in patients with
idiopathic pulmonary fibrosis. N Eng J Med 1999;341:1264-9 |
La 
10
% de la CVF
poursuite du traitement
